Bladder Cancer: Symptoms, Diagnosis and Treatment

Bladder Cancer: Symptoms, Diagnosis and Treatment

Bladder cancer is the tenth most common cancer worldwide, with approximately 570,000 new cases and 210,000 deaths annually. It predominantly affects men (3–4× higher incidence than women) and the median age at diagnosis is approximately 73. Repeat treatment and surveillance can create a substantial long-term burden. Follow-up after non-muscle-invasive disease is risk-based; not every patient needs lifelong cystoscopy.

The incidence of bladder cancer in China is rising, partly due to ageing demographics, continued high smoking rates, and increasing occupational and environmental exposures. Bladder cancer accounts for approximately 5% of all cancers in Chinese men.

Types of Bladder Cancer

Urothelial Carcinoma (Transitional Cell Carcinoma — TCC)

Accounts for approximately 90% of all bladder cancers in Western countries (and >80% in China). Arises from the transitional epithelium (urothelium) lining the entire urinary tract — from the renal pelvis through the ureters, bladder, and urethra. The bladder is the most common site.

Urothelial carcinoma may also arise in the upper urinary tract (renal pelvis, ureter) — termed upper tract urothelial carcinoma (UTUC) — managed differently but with the same pathological principles.

Other Types

• Squamous cell carcinoma (~5%) — associated with chronic bladder inflammation (catheterisation, schistosomiasis infection — common in Middle East/Africa); tends to be muscle-invasive at diagnosis
• Adenocarcinoma (~2%) — rare; may arise from urachal remnants or bladder exstrophy
• Small cell carcinoma — very rare; aggressive; treated similarly to small cell lung cancer
• Sarcoma / lymphoma — extremely rare primary bladder tumours

The Critical Staging Distinction: NMIBC vs MIBC

The most important clinical distinction in bladder cancer management:

	Non-Muscle-Invasive Bladder Cancer (NMIBC)	Muscle-Invasive Bladder Cancer (MIBC)
Stage	Ta, T1, CIS	T2–T4
Invasion	Confined to mucosa/lamina propria; does not penetrate detrusor muscle	Invades detrusor muscle (T2) or beyond
Proportion	~75% at diagnosis	~25% at diagnosis
Treatment	Transurethral resection (TURBT) + intravesical therapy	Radical cystectomy or selected bladder-preserving multimodal treatment
5-year survival	85–95% (low-risk); 50–70% (high-risk)	50–60% (T2); 20–30% (T3–4)
Surveillance	Risk-based cystoscopic follow-up	Follow-up for recurrence and metastasis

Carcinoma in situ (CIS): flat, high-grade urothelial lesion confined to the mucosa; may not be visible on cystoscopy; multifocal; high risk of progression to MIBC without treatment; classified as high-risk NMIBC.

Causes and Risk Factors

Smoking

The dominant modifiable risk factor — responsible for approximately 50% of bladder cancer cases. Cigarette smoking increases bladder cancer risk approximately 4-fold; pipe and cigar smoking also increase bladder cancer risk, but should not be assumed to confer the same risk as cigarette smoking. Carcinogenic arylamines and nitrosamines in tobacco are excreted by the kidney, concentrated in urine, and remain in prolonged contact with the urothelium. Smoking cessation reduces risk over time but the excess risk never fully returns to baseline.

Occupational Carcinogens

Aromatic amines used in chemical, dye, rubber, textile, leather, and paint industries. The classic occupational exposure is 2-naphthylamine and benzidine — historically used in dye manufacture. Risk remains elevated for 20–40 years after exposure. Current occupational exposure is regulated in most countries, but legacy exposure remains a significant source.

Chronic Irritation and Inflammation

• Urinary schistosomiasis (Schistosoma haematobium) — endemic in Africa and Middle East; eggs deposited in the bladder wall cause chronic inflammation; associated with squamous cell carcinoma rather than TCC
• Chronic indwelling urinary catheterisation — long-term catheter use in spinal cord injury
• Recurrent UTIs — chronic bacterial cystitis contributes marginally

Other Risk Factors

• Age — strong age association; median diagnosis 73 years
• Male sex — 3–4× higher than female; partly explained by higher smoking rates historically but likely also hormonal and metabolic factors
• Pelvic radiotherapy — prior radiation for prostate, cervical, or rectal cancer increases bladder cancer risk 2–4× after 10+ years
• Cyclophosphamide chemotherapy — alkylating agent metabolite acrolein is directly toxic to urothelium; increases transitional cell carcinoma risk
• Arsenic exposure — drinking water contamination in parts of Asia and South America
• Family history — small increased risk; FGFR3 and other genetic variants confer susceptibility

Symptoms

Haematuria (Blood in Urine)

The cardinal and most important symptom — present in approximately 85–90% of patients at diagnosis.

Macroscopic haematuria (frank blood visible in urine): even a single painless episode needs urgent medical assessment. Causes include bladder cancer and other urinary-tract conditions; a clinician should determine the cause and select appropriate investigations.

Microscopic haematuria (blood in urine that is not visible): requires confirmation by urine microscopy. A positive dipstick alone is not diagnostic and should prompt microscopic evaluation. Further assessment depends on the confirmed findings, possible benign causes and individual cancer-risk factors.

Haematuria in bladder cancer is classically:

• Painless — distinguishes it from UTI-related haematuria (which is usually painful)
• Intermittent — may be present in one sample and absent for weeks; does not exclude cancer
• Total (blood present throughout the urine stream) — suggests a bladder or upper tract source rather than urethra

Other Symptoms

Storage LUTS (urgency, frequency, dysuria) — may indicate CIS (carcinoma in situ), which causes bladder irritability without a visible lesion.

Flank pain / loin pain — ureteric obstruction by a tumour near the ureteric orifice or upper tract disease.

Pelvic pain, bone pain, leg oedema — features of locally advanced or metastatic disease.

Bladder cancer may also be an incidental finding on imaging (CT, ultrasound) performed for another indication.

Diagnosis and Staging

Cystoscopy

The essential diagnostic investigation. A rigid or flexible cystoscope is passed via the urethra into the bladder under local anaesthesia (flexible) or general anaesthesia (rigid) — providing direct visualisation of the urothelium and any suspicious lesions.

Flexible cystoscopy — outpatient procedure under local urethral anaesthesia; standard initial investigation for haematuria; can identify lesions and can also permit small biopsies through the instrument. A separate TURBT may still be needed for adequate tumour removal and staging.

Rigid cystoscopy + TURBT — under general or spinal anaesthesia; allows simultaneous resection of visible tumours (see TURBT, below).

Enhanced cystoscopy techniques improve detection of flat lesions (CIS):

• Photodynamic diagnosis (PDD / blue light cystoscopy): hexaminolevulinate instilled intravesically accumulates selectively in tumour cells, which fluoresce red under blue light — detects CIS and flat lesions missed by standard white-light cystoscopy in approximately 20–30% of cases
• Narrow-band imaging (NBI): optical filter enhances contrast of mucosal vasculature; improves detection of small and flat tumours

Transurethral Resection of Bladder Tumour (TURBT)

The principal diagnostic and therapeutic procedure for bladder tumours. Under general or spinal anaesthesia, the resectoscope is passed cystoscopically; the tumour is resected down to detrusor muscle and sent for histological analysis.

Histological analysis provides:

• Cell type — urothelial, squamous, adenocarcinoma
• Grade — low-grade tumours generally have lower progression risk than high-grade tumours, but can still recur frequently. Grade alone does not define recurrence risk
• Depth of invasion (T stage) — presence or absence of muscularis propria (detrusor) invasion is critical
• Presence of CIS

Re-TURBT (second-look TURBT): EAU recommends repeat resection after incomplete or uncertain initial resection, for T1 tumours, or when detrusor muscle is absent from the specimen except in Ta low-grade/G1 tumours and primary CIS. When indicated, it is usually performed within 2–6 weeks.

CT Urography (CTU)

CT of the kidneys, ureters, and bladder with contrast — evaluates the upper urinary tract for synchronous urothelial tumours (occur in 2–5% of bladder cancer patients); assesses for pelvic lymph node enlargement and distant metastases in staging of MIBC.

Urinary Cytology

Microscopic examination of urothelial cells in a voided urine specimen. High sensitivity for high-grade TCC and CIS but low sensitivity for low-grade tumours. Useful as an adjunct to cystoscopy and for surveillance.

Staging (TNM)

Stage	Description
Ta	Non-invasive papillary tumour
CIS	Flat high-grade intraepithelial carcinoma
T1	Invades lamina propria (subepithelial connective tissue)
T2a	Invades inner half of detrusor muscle
T2b	Invades outer half of detrusor muscle
T3	Invades perivesical tissue
T4	Invades adjacent organs (prostate, uterus, pelvic wall)
N1–N3	Regional lymph node involvement
M1	Distant metastasis (bone, lung, liver)

Risk stratification for NMIBC: the EAU progression-risk framework has four groups — low, intermediate, high and very high. Classification combines stage, grade, CIS and clinical factors such as age, tumour size and multiplicity; recurrence history also informs management. A single feature does not reliably assign a group. The urologist should document the applicable risk assessment and treatment implications.

Treatment

Non-Muscle-Invasive Bladder Cancer (NMIBC)

Single Instillation Intravesical Chemotherapy (Post-TURBT)

A single immediate intravesical chemotherapy instillation after TURBT can reduce recurrence in low-risk and selected other NMIBC cases; it is not appropriate for every intermediate-risk tumour. When used, EAU recommends administration within 24 hours. Omit it if bladder perforation is suspected or present, or bleeding requires bladder irrigation. The exact medicine and subsequent treatment depend on the resection and risk assessment.

Intravesical BCG (Bacillus Calmette-Guérin)

BCG is a standard intravesical treatment option for high-risk NMIBC, including many high-grade T1 tumours and CIS. Treatment should be selected by individual risk, and immediate radical cystectomy should also be discussed, particularly for very high-risk disease. BCG is a live attenuated mycobacterial strain that triggers an intense local immune response within the bladder, activating T-cells, NK cells, and macrophages against tumour cells.

Protocol: Induction course (weekly instillations for 6 weeks); maintenance courses (weekly × 3) at months 3, 6, 12, 18, 24, 30, 36 — the optimal 3-year maintenance course reduces recurrence and progression versus induction alone.

• Reduces recurrence by approximately 30–40% over chemotherapy alone
• Reduces progression to MIBC by approximately 30–40%
• Side effects: dysuria, frequency, low-grade fever (BCG cystitis — treated symptomatically); BCG sepsis — rare systemic dissemination requiring anti-tuberculosis treatment; haematuria

BCG-unresponsive disease requires specialist review; radical cystectomy remains an important option, and delaying it may carry progression risk. For selected patients, US-approved bladder-preserving options include pembrolizumab, nadofaragene firadenovec and the gemcitabine intravesical system (Inlexzo, approved in September 2025). Each has specific eligibility requirements, particularly concerning carcinoma in situ and prior BCG.

Cretostimogene is a different, investigational oncolytic virus: the developer’s current information states that it is not approved by any regulatory agency. A trial result or regulatory designation is not an approval. Local approval, access and suitability must be confirmed; US approvals are not a statement of availability in China.

Surveillance Cystoscopy

Cystoscopic follow-up is tailored to recurrence and progression risk. As an example, the EAU schedule uses:

• Low-risk: cystoscopy at 3 and 12 months, then annually, with a five-year follow-up duration.
• Intermediate-risk low-grade disease: an initial check at 3 months, then six-monthly checks for two years and annual checks thereafter, with a ten-year duration.
• High/very-high-risk disease: cystoscopy with cytology every three months for two years, then every six months until year five, and annually lifelong. Intermediate-risk high-grade disease follows the high-risk schedule.

Your team should confirm the schedule, including imaging when indicated. Do not stop surveillance without that discussion.

Muscle-Invasive Bladder Cancer (MIBC)

Neoadjuvant Chemotherapy (NAC)

Cisplatin-based combination chemotherapy (MVAC — methotrexate, vinblastine, adriamycin, cisplatin; or gemcitabine + cisplatin) given before radical cystectomy — improves 5-year overall survival by approximately 5–8% (absolute) in cisplatin-eligible patients. NAC aims to treat possible micrometastatic disease and may downstage the primary tumour; response varies, and eradication of all cancer is not guaranteed for an individual patient. A standard option before cystectomy for cisplatin-eligible patients with resectable cT2–T4a, N0 M0 MIBC, after multidisciplinary assessment. cT4b disease requires a separate, individualised treatment plan rather than automatic application of this pathway.

Radical Cystectomy

Removal of the entire bladder with bilateral pelvic lymph node dissection. The extent of additional prostate, seminal-vesicle or gynaecological-organ removal depends on tumour involvement and individual assessment; reproductive-organ-preserving approaches may be considered in carefully selected patients when oncologically appropriate. The standard curative treatment for MIBC.

Urinary diversion — the bladder must be replaced; three options:

1. Orthotopic neobladder (ileal neobladder) — a reservoir constructed from the ileum, connected directly to the urethra, allowing voiding per urethra; an option for selected patients with suitable urethral function and general health. Leakage, especially at night, and difficulty emptying can occur; some people need self-catheterisation. It is not proven to provide the best quality of life or continence for every patient
2. Ileal conduit (Bricker) — ureters anastomosed to a short segment of ileum, which exits as a stoma (urostomy) on the abdominal wall; simplest and most reliable; no internal reservoir; requires stoma bag
3. Continent cutaneous diversion (Indiana pouch, Mitrofanoff) — internal reservoir catheterised via a continent abdominal stoma; no bag; requires manual catheterisation every 4–6 hours

Robot-assisted radical cystectomy (RARC) — the da Vinci robotic system enables minimally invasive cystectomy with equivalent oncological outcomes to open surgery; reduced blood loss and faster recovery; urinary diversion can be performed intracorporeally or extracorporeally; available at specialist centres.

Complications: erectile dysfunction and loss of semen ejaculation when the prostate and seminal vesicles are removed (men). This may cause a dry orgasm and infertility; it is different from semen flowing backward into an intact bladder; sexual dysfunction and vaginal dryness (women); urinary complications (ureteric stricture, neobladder dysfunction); bowel complications.

Trimodality Therapy (Bladder-Preserving Approach)

Trimodality therapy may be an option for appropriately selected patients with MIBC, including some who are fit for cystectomy and some with disease beyond T2, after multidisciplinary assessment and shared decision-making. Selection considers tumour extent, CIS, hydronephrosis and baseline bladder function; the treatment combines complete TURBT + concurrent chemotherapy (cisplatin or 5-FU/mitomycin) + external beam radiotherapy. Bladder preservation achieved in approximately 40–50% of carefully selected patients with 5-year overall survival comparable to cystectomy in propensity-matched series. Requires close surveillance.

Metastatic/Advanced Bladder Cancer

First-line treatment is no longer described by a single chemotherapy regimen. Enfortumab vedotin plus pembrolizumab is an important first-line option for eligible advanced urothelial cancer. Its December 2023 US approval was not restricted to people eligible for cisplatin. Other approaches, including platinum-based chemotherapy and selected immunotherapy combinations, depend on fitness, prior treatment and local access.

Enfortumab vedotin + pembrolizumab: the EV-302 trial reported median overall survival of 31.5 months versus 16.1 months with platinum–gemcitabine in its initial analysis. Both cisplatin-eligible and cisplatin-ineligible patients were included. These trial medians are not an individual life-expectancy prediction.

Checkpoint inhibitors: indications differ by drug, disease setting and jurisdiction. Examples include avelumab maintenance when disease has not progressed after first-line platinum chemotherapy, and nivolumab with cisplatin/gemcitabine in eligible untreated advanced disease. Some older US metastatic urothelial indications for atezolizumab and durvalumab were withdrawn; this does not mean that every indication for either medicine is withdrawn. The oncologist must check the current indication and combination rather than select from an interchangeable list.

Erdafitinib: the January 2024 US indication concerns susceptible FGFR3 alterations detected with an approved companion test in advanced urothelial disease after prior systemic treatment. It should not be presented as a general option for any FGFR2/FGFR3 alteration after platinum. The FDA also advises against its use before PD-1/PD-L1 therapy in patients who are eligible for that therapy but have not received it. Confirm local regulatory requirements and suitability.

Bladder Cancer Care in China

Ask the receiving urology and oncology team to review the pathology, grade, stage, prior BCG or systemic treatment and existing scans before proposing a pathway. Confirm whether cystoscopy, TURBT, further imaging or pathology review is needed.

For proposed surgery, discuss urinary diversion, sexual function, rehabilitation and follow-up. For bladder-preserving or drug treatment, confirm the exact indication, local approval, current availability and surveillance requirements. Obtain an itemised hospital quotation and confirm language support and any PriumCare coordination separately; this article does not establish comparative cost savings or a particular institution’s capabilities.

Contact a PriumCare care navigator to arrange a haematuria assessment, cystoscopy, or bladder cancer treatment consultation.

---

Sources and editorial correction

• NHS: cystoscopy and biopsy.

• EAU: NMIBC follow-up and disease management.

• FDA: Adstiladrin and Inlexzo approval, September 2025.

• CG Oncology: cretostimogene investigational status.

• EAU: invasive bladder cancer management.

• NHS: neobladder information.

• American Cancer Society: cystectomy and sexual effects.

• FDA: EV plus pembrolizumab, December 2023.

• NCI: avelumab.

• FDA: nivolumab combination.

• FDA: withdrawn oncology indications.

• FDA: erdafitinib, January 2024.

• Additional targeted source.

• Additional targeted source.

• Additional targeted source.

• Additional targeted source.

Second-pass editorial clarification: 25 October 2026. Additional checks addressed the specific definitions, treatment eligibility and risk-classification statements documented here. This does not constitute a whole-article medical review.

Editorial source correction: 25 October 2026. Targeted checks addressed cystoscopy, risk-based surveillance, urinary diversion and systemic-treatment/approval claims. This is not a clinical review of the whole article. No named medical reviewer is claimed. Original publication date is retained.

Targeted tobacco-risk and treatment-stage clarification

Editorial source check: 26 October 2026. This update checks only the comparison of tobacco-product risks and eligibility for the chemotherapy-before-cystectomy pathway clarified above. It is not a whole-article medical review, adds no named clinical reviewer, and retains the original publication date.

• IARC-authored original study: cigar, pipe and cigarette smoking and bladder cancer
• EAU guidelines: neoadjuvant chemotherapy and radical cystectomy selection
• NCI PDQ: bladder cancer staging and treatment options

Targeted BCG selection and cystectomy-extent clarification

Editorial source check: 26 October 2026. This update checks only risk-based selection of BCG versus discussion of immediate radical cystectomy and the individual extent of adjacent reproductive-organ removal described above. It is not a whole-article medical review, adds no named clinical reviewer, and retains the original publication date.

• EAU NMIBC guideline: risk-based BCG and radical cystectomy decisions
• EAU MIBC guideline: radical cystectomy and selected organ-preserving techniques

Targeted editorial source check — 26 October 2026: only trimodality-treatment candidacy was checked against the EAU MIBC guideline, sections 6.1 and 6.8.1.a. This is not a whole-article medical review; it adds no named clinical reviewer and retains the original publication date. Other treatment details and outcome figures were not reassessed in this check.

Targeted editorial source check — 26 October 2026: only the statement about the intended micrometastatic treatment and possible tumour downstaging from neoadjuvant chemotherapy was reassessed against the EAU MIBC guideline, section 6.5.1.a. These are treatment aims and possible benefits, not a guarantee of individual cancer eradication. This is not a whole-article medical review, adds no named clinical reviewer and retains the original publication date.

Targeted editorial source check — 26 October 2026: only the distinction between dipstick screening, microscopic confirmation and subsequent individual assessment was reassessed against the AUA/SUFU 2025 microhaematuria guideline. A positive dipstick alone does not establish microscopic haematuria. This is not a whole-article medical review, adds no named clinical reviewer and retains the original publication date.

---

Targeted editorial source check — 26 October 2026: Only the passage on visible blood in urine, its possible causes and the need for urgent clinical assessment was checked against NHS blood-in-urine advice and NIH/NIDDK haematuria information. This is not a whole-article medical review, adds no named clinical reviewer and retains the original publication date.